Regulators in the U.S. and the European Union agreed to review Biogen’s applications for approval of a higher dose Spinraza ...
Ozanimodâ–¼ is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active ...
We now have two FDA-approved disease-modifying treatments for Alzheimer's disease, and hundreds of clinical trials are ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
However, the sector faces another kind of risk, with a new administration in charge in Washington.
AbbVie ABBV announced that it has entered into a collaboration and option-to-license agreement with the San Diego-based ...
BIIB's regulatory filings are supported by late-stage data, which show that treatment with a higher Spinraza dose improves motor function in infants with SMA.
Biogen’s applications for the higher dose regimen of SMA drug Spinraza are now under review in the US and Europe.
In a report released today, Cory Jubinville, PhD from LifeSci Capital maintained a Buy rating on Larimar Therapeutics (LRMR – Research Report), ...
An investigational higher dose of spinal muscular atrophy drug nusinersen gains attention as the FDA and European Medicines Agency (EMA) considerate it as an alternative than the current lower ...
The Sackler family, owners of Purdue Pharma, reached a $7.4 billion settlement to resolve mass opioid litigation. The Department of Justice filed a civil lawsuit against Walgreens over allegations it ...